Clinical Trial Update: Study Evaluating the Safety,Tolerability, PK and PD of SAM-531 in the Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating SAM-531 for Alzheimer's disease has completed, focusing on safety, tolerability, pharmacokinetics and pharmacodynamics; sponsor Wyeth i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SAM-531

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED